3.3 Clinical outcomes and cost‐saving effect
There were 171 patients with hypertension in the study. Post-intervention group showed lower levels in SBP and DBP compared to the pre-intervention group (SBP: 134.56 ± 12.38 vs 149.08 ± 19.75, P = 0.000; DBP: 78.01 ± 9.78 vs 84.56 ± 11.34, P=0.000). There were 73 patients with hyperlipidemia in the study. There were statistically significant changes in TC, LDL-C and TG between the pre-intervention group and the post-intervention group (Table 4).
The average costs of medications per patient for every month were 387.72±168.48 Ren Min Bi (RMB) in the pre-intervention group and 355.17±180.03 RMB in the post-intervention group. The cost of antihypertensive drugs was markedly declined (230.40±138.14 vs 206.58±112.74, P=0.001). However, the cost of lipid modifying agents was increased (181.12±106.14 vs 242.67±175.56, P=0.006; Table 5).